NYSE:ENZ - Enzo Biochem Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.58 0.00 (0.00 %) (As of 04/18/2019 04:00 PM ET)Previous Close$3.58Today's Range$3.50 - $3.6452-Week Range$2.32 - $6.89Volume270,837 shsAverage Volume187,594 shsMarket Capitalization$169.12 millionP/E RatioN/ADividend YieldN/ABeta1.29 ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York. Receive ENZ News and Ratings via Email Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:ENZ Previous Symbol CUSIPN/A CIK316253 Webwww.enzo.com Phone212-583-0100Debt Debt-to-Equity Ratio0.07 Current Ratio3.83 Quick Ratio3.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$104.71 million Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book2.08Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,320,000.00 Net Margins-25.55% Return on Equity-29.83% Return on Assets-23.74%Miscellaneous Employees460 Outstanding Shares47,241,000Market Cap$169.12 million Next Earnings Date6/10/2019 (Estimated) OptionableOptionable Enzo Biochem (NYSE:ENZ) Frequently Asked Questions What is Enzo Biochem's stock symbol? Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ." How were Enzo Biochem's earnings last quarter? Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings data on Monday, March, 11th. The medical research company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.05. The medical research company had revenue of $19.33 million for the quarter. Enzo Biochem had a negative return on equity of 29.83% and a negative net margin of 25.55%. View Enzo Biochem's Earnings History. When is Enzo Biochem's next earnings date? Enzo Biochem is scheduled to release their next quarterly earnings announcement on Monday, June 10th 2019. View Earnings Estimates for Enzo Biochem. Has Enzo Biochem been receiving favorable news coverage? Media stories about ENZ stock have trended positive this week, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enzo Biochem earned a news sentiment score of 2.9 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. Are investors shorting Enzo Biochem? Enzo Biochem saw a increase in short interest in March. As of March 29th, there was short interest totalling 1,091,233 shares, an increase of 42.7% from the March 15th total of 764,561 shares. Based on an average daily volume of 307,201 shares, the short-interest ratio is presently 3.6 days. Approximately 2.5% of the company's shares are sold short. View Enzo Biochem's Current Options Chain. Who are some of Enzo Biochem's key competitors? Some companies that are related to Enzo Biochem include RadNet (RDNT), Celcuity (CELC), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Biocept (BIOC), First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI), Cancer Genetics (CGIX), OpGen (OPGN), Aeon Global Health (AGHC), Avant Diagnostics (AVDX) and Foundation Medicine (FMI). What other stocks do shareholders of Enzo Biochem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include Onelife Technologies (OLMM), Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), AbbVie (ABBV), Array Biopharma (ARRY), Cytokinetics (CYTK), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Bristol-Myers Squibb (BMY) and Advanced Micro Devices (AMD). Who are Enzo Biochem's key executives? Enzo Biochem's management team includes the folowing people: Dr. Elazar Rabbani, Co-Founder, Chairman, CEO & Sec. (Age 76)Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 69)Mr. James Michael O'Brien, Exec. VP of Fin. (Age 53)Dr. Dieter Schapfel, Chief Medical Director - Enzo Clinical Labs (Age 56)Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 61) Who are Enzo Biochem's major shareholders? Enzo Biochem's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Corrado Advisors LLC (0.46%). Company insiders that own Enzo Biochem stock include Barry W Weiner, Bruce A Hanna, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Institutional Ownership Trends for Enzo Biochem. Which institutional investors are selling Enzo Biochem stock? ENZ stock was sold by a variety of institutional investors in the last quarter, including Corrado Advisors LLC. View Insider Buying and Selling for Enzo Biochem. How do I buy shares of Enzo Biochem? Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Enzo Biochem's stock price today? One share of ENZ stock can currently be purchased for approximately $3.58. How big of a company is Enzo Biochem? Enzo Biochem has a market capitalization of $169.12 million and generates $104.71 million in revenue each year. Enzo Biochem employs 460 workers across the globe. What is Enzo Biochem's official website? The official website for Enzo Biochem is http://www.enzo.com. How can I contact Enzo Biochem? Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100. MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 146 (Vote Outperform)Underperform Votes: 153 (Vote Underperform)Total Votes: 299MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe ENZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/18/2019 by MarketBeat.com StaffFeatured Article: Why are percentage gainers important?